People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel mechanisms of action.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

were among the most effective treatments for treatment-resistant depression, usually defined as severe depressive symptoms that have not improved despite treatment with at least two standard ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

an inhalable treatment for treatment-resistant depression (TRD), demonstrating a significant placebo-adjusted reduction in depression scores as measured by the MADRS scale on Day 8. The trial ...